These past few days we’ve seen some interesting developments in the world of short-acting insulin. On Friday Novo Nordisk (NYSE: NVO) per a press release announced;
“Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA's decision comes after Fiasp® in clinical trials demonstrated benefits for people in need of improved overall glucose control.”
And just this morning MannKind (NASDAQ: MNKD) announced;
“MannKind Corporation (Nasdaq and TASE: MNKD) today announced that the U . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.